Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
Makhmujan RashitovMolly F FrankeLetizia TrevisiGulzhanat BekbolatovaJulia ShalimovaGafurzhan EshmetovSagit BektasovAllison LaHoodNataliya ArlyapovaElna OssoAskar YedilbayevOleksandr KorotychAnisoara CiobanuAlena SkrahinaCarole D MitnickKwonjune SeungYerkebulan AlgozhinMichael L RichPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
All regimens demonstrated excellent safety and effectiveness, expanding the potential treatment options for patients, providers, and programs.
Keyphrases
- multidrug resistant
- end stage renal disease
- randomized controlled trial
- mycobacterium tuberculosis
- systematic review
- ejection fraction
- newly diagnosed
- chronic kidney disease
- pulmonary tuberculosis
- public health
- prognostic factors
- peritoneal dialysis
- drug resistant
- gram negative
- risk assessment
- human immunodeficiency virus
- climate change
- human health